Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 4/20 | 0.67 |
| ▸ | TUBB | P07437 | 4/20 | 0.67 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.67 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.67 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.67 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.67 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.67 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.67 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.67 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.67 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.67 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.67 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.67 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.67 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.67 |
| ▸ | MET | P08581 | 2/20 | 0.67 |
| ▸ | CDK9 | P50750 | 2/20 | 0.67 |
| ▸ | KDR | P35968 | 6/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Luxabendazole SCHEMBL1193261 | 0.99 | TUBB4A (0.66) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Luxabendazole SCHEMBL6055930 | 0.92 | TUBB4A (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Luxabendazole SCHEMBL29765623 | 0.92 | TUBB4A (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL11868259 | 0.91 | TUBB4A (0.72) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL11868920 | 0.90 | TUBB4A (0.68) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5036244 | 0.90 | MET (0.55) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL11878160 | 0.89 | TUBB4A (0.67) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL11870396 | 0.89 | TUBB4A (0.73) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL14300495 | 0.89 | TUBB4A (0.63) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5033395 | 0.88 | TUBB4A (0.64) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021151122-A1 | THERAPEUTIC COMPOSITIONS COMPRISING SODIUM DIACETATE FOR CANCER PAIN AND METABOLIC ABNORMALITIES | THAI MINH PHARMACEUTIAL JOINT STOCK COMPANY (VN) | 2021-07-29 | — | — | WO | claimed |
| WO-2018148392-A1 | IN VIVO MODEL FOR PARASITIC WORM INFECTION AND METHODS FOR EVALUATING ANTIPARASITIC COMPOUNDS, INCLUDING COMPOUNDS ACTIVE AGAINST CANINE HEARTWORM | MERIAL, INC. (US) | 2018-08-16 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-1830847-B1 | TREATMENT FOR CANCER | PITNEY PHARMACEUTICALS PTY LTD (AU) | 2014-11-19 | — | — | EP | claimed |
| EP-1784181-B1 | VEGF INHIBITION | NEWSOUTH INNOVATIONS PTY LTD (AU) | 2013-08-07 | — | — | EP | claimed |
| US-20120214856-A1 | TREATMENT FOR CANCER | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2012-08-23 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20090286838-A1 | TREATMENT FOR CANCER | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2009-11-19 | — | — | US | claimed |
| EP-1784181-A4 | VEGF INHIBITION | NEWSOUTH INNOVATIONS PTY LTD (AU) | 2009-06-03 | — | — | EP | claimed |
| US-20090105317-A1 | VEGF Inhibition | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2009-04-23 | — | — | US | claimed |
| CN-1117267-A | Synergistic composition containing benzimidazole anthelmintics and methylenedioxyphenyl compounds | UNIV DUNDEE (GB) | 1996-02-21 | — | — | CN | claimed |
| EP-0682518-A1 | SYNERGISTIC COMPOSITIONS CONTAINING BENZIMIDAZOLE ANTHELMINTICS AND METHYLENEDIOXYPHENYL COMPOUNDS | BTG INTERNATIONAL LIMITED (GB) | 1995-11-22 | — | — | EP | claimed |
| US-5434163-A | Administering benzimidazole derivative | THE MEDICAL COLLEGE OF PENNSYLVANIA (US) | 1995-07-18 | — | — | US | claimed |
| WO-1994028887-A1 | SYNERGISTIC ANTHELMINTIC COMPOSITIONS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1994-12-22 | — | — | WO | claimed |
| WO-1994027598-A1 | ANTIPARASITIC COMPOSITIONS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1994-12-08 | — | — | WO | claimed |
| WO-1994017798-A1 | SYNERGISTIC COMPOSITIONS CONTAINING BENZIMIDAZOLE ANTHELMINTICS AND METHYLENEDIOXYPHENYL COMPOUNDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 1994-08-18 | — | — | WO | claimed |
| EP-0505389-A4 | ANTIPARASITIC COMPOSITION FOR ANIMAL USE | — | 1992-12-02 | — | — | EP | claimed |
| EP-0505389-A1 | ANTIPARASITIC COMPOSITION FOR ANIMAL USE. | SMITHKLINE BEECHAM CORP (US) | 1992-09-30 | — | — | EP | claimed |
| WO-1991008669-A1 | ANTIPARASITIC COMPOSITION FOR ANIMAL USE | SMITHKLINE BEECHAM CORPORATION (US) | 1991-06-27 | — | — | WO | claimed |
| EP-0279343-B1 | COMBINATIONS OF ANTHELMINTICALLY ACTIVE AGENTS | BAYER AG (DE) | 1991-06-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105317-A1 | VEGF Inhibition | VEGFA, PGF, HDGF | TUBB4A 612/4885TUBB 632/4885TUBA3C 1892/4885 |
| US-20120214856-A1 | TREATMENT FOR CANCER | CCNI, CDK15, MKI67 | TUBB4A 41/4885TUBB 33/4885TUBA3C 47/4885 |
| US-20090286838-A1 | TREATMENT FOR CANCER | CCNI, CDK15, MKI67 | TUBB4A 42/4885TUBB 33/4885TUBA3C 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.